The global Liposome Injection market size is predicted to grow from US$ 721 million in 2025 to US$ 996 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.

Liposomes are lipid microcapsules composed of an amphiphilic lipid bilayer (monolayer) and/or a series of concentric discontinuous aqueous compartments separated by a series of multiple amphiphilic bilayers. In liposome drugs, the drug is contained in liposomes. In general, water-soluble drugs are often encapsulated in the aqueous compartment, and lipophilic drugs are encapsulated in the lipid bilayer of the liposome.

According to the Global Use of Medicines 2023 released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, Chinas drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few years: From the perspective of demand, the trend of population aging, the increase of residents? wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the Healthy China 2030 Planning Outline, and Healthy China has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses. Global Use of Medicines 2023 shows that, based on net ex-factory prices, the U.S. market will spend about $62.9 billion on medicines in 2022. Overall growth slows as the Inflation Reduction Act (IRA) spends $64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years, with ex-factory discounts and rebates in the drug pipeline , the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

Infinity Market Research newest research report, the ?Liposome Injection Industry Forecast? looks at past sales and reviews total world Liposome Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Liposome Injection sales for 2025 through 2031. With Liposome Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposome Injection industry.

This Insight Report provides a comprehensive analysis of the global Liposome Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposome Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Liposome Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposome Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposome Injection.

This report presents a comprehensive overview, market shares, and growth opportunities of Liposome Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Doxorubicin Hydrochloride Liposome Injection
    Mitoxantrone Hydrochloride Liposome Injection
    Irinotecan Hydrochloride Liposome Injection
    Others

Segmentation by Application:

    Malignant Tumor Treatment
    Infection Treatment
    Post-operative Pain Relief
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    CSPC
    Luye Pharma
    Fudan Zhangjiang
    Nanjing Cisco
    Qilu Pharmaceutical
    Sichuan Kelun
    Modern Medicine
    Eudinamis
    Indiamart
    Getwelloncology
    Polymun

Key Questions Addressed in this Report

What is the 10-year outlook for the global Liposome Injection market?
What factors are driving Liposome Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposome Injection market opportunities vary by end market size?
How does Liposome Injection break out by Type, by Application?